NOT KNOWN DETAILS ABOUT SIRPIGLENASTAT CLINICAL TRIAL

“This specific prodrug layout designed DON specific to its intended location (tumor) and have significantly less of an influence on nutritious cells somewhere else.”It has anticancer consequences by specifically focusing on tumor metabolism and simultaneously inducing a powerful antitumor immune response with immunomodulatory and antineoplastic